CTL019
ALL Has Potential to Relapse After CAR T-Cell Therapy
B-cell acute lymphoblastic leukemia can recur when leukemic cells become resistant to chimeric antigen receptor ...
OCTOBER 26, 2018
CTL019 Receives Breakthrough Designation for Relapsed/Refractory DLBCL
The drug was granted breakthrough therapy designation for the treatment of adult patients with r/r diffuse large ...
APRIL 18, 2017
CAR-T Therapy Granted Priority Review for B-Cell ALL
The drug was granted priority review for the treatment of relapsed and refractory pediatric and young adult ...
MARCH 30, 2017
Load more